A series of 22 novel metronidazole-triazole-styryl hybrids were synthesized and evaluated for their in vitro antiamoebic activity against HM1: IMSS strain of Entamoeba histolytica. Some of the hybrids were found to be more active (IC50 = 0.12-0.35 μM) than the reference drug metronidazole (IC50 = 1.79 μM). The most active compounds were found to be non-toxic (up to 50 μM) against the Vero cells showing a good safety profile of these hybrids. The docking and ADMET studies were also conducted to investigate the probable mode of action. Docking studies showed significant binding affinity in the active site of E. histolytica thioredoxin reductase (EhTrR) protein.
Keywords: Docking studies; Entamoeba histolytica; Metronidazole; Thioredoxin reductase; Triazole.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.